More Updates from SABCS 2010

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Tim Cortese

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

June 19th 2025

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

Radhika Appaya;Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD

Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone

PATHFINDER 2 data build upon bolstered cancer detection rates by the multi-cancer early detection test found in a previously published PATHFINDER study.

Immunotherapy Rechallenge Exhibits Feasibility in Pretreated ES-SCLC

PATHFINDER 2 data build upon bolstered cancer detection rates by the multi-cancer early detection test found in a previously published PATHFINDER study.

Related Content

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Tim Cortese

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

June 19th 2025

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone